Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/16140919/ below:

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients

Affiliations

• ¹ Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

• PMID: 16140919
• DOI: 10.1158/0008-5472.CAN-05-1705

Item in Clipboard

Ximing Tang et al. Cancer Res. 2005.

• ¹ Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

• PMID: 16140919
• DOI: 10.1158/0008-5472.CAN-05-1705

Item in Clipboard

To determine whether EGFR tyrosine kinase domain mutations are early events in the pathogenesis of lung adenocarcinomas, we tested for the presence of EGFR mutations in histologically normal bronchial and bronchiolar epithelia from lung adenocarcinomas bearing the common EGFR mutations. DNA was extracted from microdissected tissue obtained from 21 tumors with known EGFR mutations, 16 tumors without mutation, and 90 sites of normal bronchial and bronchiolar epithelium from the same surgical specimens. With the use of PCR and direct DNA sequencing, EGFR mutations identical to the tumors were detected in the normal respiratory epithelium in 9 of 21 (43%) patients with EGFR mutant adenocarcinomas but none in patients without mutation in the tumors. The finding of mutations being more frequent in normal epithelium within tumor (43%) than in adjacent sites (24%) suggests a localized field effect phenomenon. Our findings indicate that mutation of the tyrosine kinase domain of EGFR is an early event in the pathogenesis of lung adenocarcinomas, and suggest EGFR mutations as an early detection marker and chemoprevention target.

PubMed Disclaimer

• EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

  Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY. Bae NC, et al. Cancer Genet Cytogenet. 2007 Mar;173(2):107-13. doi: 10.1016/j.cancergencyto.2006.10.007. Cancer Genet Cytogenet. 2007. PMID: 17321325

• Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

  Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF. Shigematsu H, et al. Cancer Res. 2005 Mar 1;65(5):1642-6. doi: 10.1158/0008-5472.CAN-04-4235. Cancer Res. 2005. PMID: 15753357

• Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.

  Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Raso MG, et al. Clin Cancer Res. 2009 Sep 1;15(17):5359-68. doi: 10.1158/1078-0432.CCR-09-0033. Epub 2009 Aug 25. Clin Cancer Res. 2009. PMID: 19706809 Free PMC article.

• Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation.

  Mäkinen N, Zhou M, Bemus M, Nevin J, Nag A, Chen R, Colson YL, Thorner AR, Oxnard GR, Meyerson M, Sholl LM. Mäkinen N, et al. JTO Clin Res Rep. 2021 Jan 30;2(4):100146. doi: 10.1016/j.jtocrr.2021.100146. eCollection 2021 Apr. JTO Clin Res Rep. 2021. PMID: 34590005 Free PMC article.

• QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC.

  Yang YP, Ma YX, Huang Y, Zhao YY, Fang WF, Hong SD, Tian Y, Xue C, Sheng J, Zhang L. Yang YP, et al. Sci Rep. 2015 Jul 3;5:11934. doi: 10.1038/srep11934. Sci Rep. 2015. PMID: 26137916 Free PMC article. Clinical Trial.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3